NTI

2.78%

7.0¢ neurotech international limited

The response above is to a comment from @Tony barber.The chart...

First 67 Last

ttppxx

106 Posts.

18/04/24

12:36

Post #: 73405993

Originally posted by ttppxx: ↑
QUESTION:“What was the keycatalyst for Neuron? FDA approval?”

RESPONSE

A) The chart I shared (extracted from NextInvestors) is an exact share price tracker for Neuren Pharmaceuticals, from 2021 toJanuary 2024 (not just 2021). The comments that Next have inserted, show the'catalysts' that preceded (or ‘led’) to the share price re-rates.

B) I have redone this as a table (attached) andextracted additional information from Neuren (just theannouncements). As can be seen, whenmatching events to share price re-rates, the Top 3 SP catalysts were:
1) Trial results (Retts) - (Announced 6th of Dec 2021). This caused the biggestjump to date!
2) FDA approval - (Announced 14th of March 2023). This caused the nextbiggest jump to date.
3) Trial results (Phelan-McDermid) - (Announced 18 Dec 2023). This is not markedon the Next Investors chart - they limited their comments (on the chart) to Rett Syndrome!

DATE
EVENT (CATALYST)
SHARE PRICE MOVES
(5 days)
1
07 Dec 2021
ANN: Positive topline results from Phase 3 trial in Rett syndrome
$1.70 to $4.00 (135%)
2
14 Mar 2023
ANN: FDA approves Daybue - the first treatment for Rett syndrome
$7.60 to $12.80 (68%)
3
18 Dec 2023
ANN: P2 trial shows significant improvements in Phelan-McDermid
$16.00 to $24.00 (50%)
The share price movements within those 2 to 5days post results were much higher than what happened in the interveningperiods: 6% per month rise from Rett P3 results to FDA announcement, and 2.7%per month rice post the FDA announcement up to the P2 Phelan-McDermid trialresults readout.

Indeed, NT1 is still behind. This is shownclearly on the Next Investors chart.
Expand
The response above is to a comment from @Tony barber.

The chart below (from Next Investors) seems well placed as part of a response to the question about catalysts that propelled Neuren to the very high SP that it is now at.

NTI is behind for sure, but still on a path that may have differences, but is not completely dissimilar to how Neuren travelled.

NTI Price at posting: 10.5¢ Sentiment: Buy Disclosure: Held

Upvote

0 Great analysis

Top Stories

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

SVL

Silver Mines models five new calderas close to 396Moz Bowdens deposit

SS1

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

AVA

Ava Risk Group expands US presence with A$0.7M Substation Deal

CMX

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Microcap Wrap: 5 explorers with news out today

RCE

Recce's R327 found effective against E.coli during clinical trial

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

LRV

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

LU7

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

There are more pages in this discussion • 20 more messages in this thread...

First 67 Last

Add NTI (ASX) to my watchlist

(20min delay)
Last 7.0¢		Change -0.002(2.78%)		Mkt cap ! $71.21M

Open	High	Low	Value	Volume
7.3¢	7.3¢	7.0¢	$86.59K	1.228M

Buyers (Bids)

No.	Vol.	Price($)
1	6000	7.1¢

Sellers (Offers)

Price($)	Vol.	No.
7.5¢	72226	1

View Market Depth

No.	Vol.	Price($)
2	138838	0.070
2	62535	0.069
1	973610	0.068
2	159208	0.067
1	150000	0.066

Price($)	Vol.	No.
0.075	72226	1
0.076	100000	1
0.077	116800	2
0.078	94680	3
0.079	300000	1

Last trade - 15.38pm 28/06/2024 (20 minute delay)

NTI (ASX) Chart

The response above is to a comment from @Tony barber.The chart...

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Ava Risk Group expands US presence with A$0.7M Substation Deal

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Microcap Wrap: 5 explorers with news out today

Recce's R327 found effective against E.coli during clinical trial

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

	DATE	EVENT (CATALYST)	SHARE PRICE MOVES (5 days)
1	07 Dec 2021	ANN: Positive topline results from Phase 3 trial in Rett syndrome	$1.70 to $4.00 (135%)
2	14 Mar 2023	ANN: FDA approves Daybue - the first treatment for Rett syndrome	$7.60 to $12.80 (68%)
3	18 Dec 2023	ANN: P2 trial shows significant improvements in Phelan-McDermid	$16.00 to $24.00 (50%)

The response above is to a comment from @Tony barber.The chart...

Top Stories

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Ava Risk Group expands US presence with A$0.7M Substation Deal

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Microcap Wrap: 5 explorers with news out today

Recce's R327 found effective against E.coli during clinical trial

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News